Copyright
©The Author(s) 2025.
World J Clin Oncol. Apr 24, 2025; 16(4): 102199
Published online Apr 24, 2025. doi: 10.5306/wjco.v16.i4.102199
Published online Apr 24, 2025. doi: 10.5306/wjco.v16.i4.102199
Table 2 Clinical efficacy of anlotinib combined with nab-ptx in second-line or above treatment for advanced gastric cancer
Clinical efficacy | Patient No. | Proportion (%) |
Complete response | 0 | 0 |
Partial response | 16 | 44.44 (16/36) |
Stable response | 12 | 33.33 (12/36) |
Progressive disease | 8 | 22.23 (8/36) |
Objective response | 44.44 | |
Median PFS | 6.0 months | |
Disease control rate | 77.78 | |
Median OS | 12.0 months |
- Citation: Liu WM, Liu YR, Peng Y, Tang J, Li XB. Combination of anlotinib and albumin-bound paclitaxel in 2nd line and above treatment of advanced gastric cancer: A retrospective study. World J Clin Oncol 2025; 16(4): 102199
- URL: https://www.wjgnet.com/2218-4333/full/v16/i4/102199.htm
- DOI: https://dx.doi.org/10.5306/wjco.v16.i4.102199